top of page

Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry

May 30, 2025

1 min read

Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation.

https://vimeo.com/1089138457?share=copy

Recent Posts

Formation Bio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - it is a step in its plan to make drug development more efficient and become 'the next pharma'

Formation Bio announced a $600M fund it will use to acquire 10–15 drug programs over the next 3–5 years - it is a step in its plan to make drug development more efficient and become 'the next pharma'

Zentalis aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive

Zentalis aims to deliver to the ovarian cancer community a precision medicine approach - a targeted (WEE1) oral therapy for patients who are Cyclin E1 positive

BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab

BIO-Europe 2026: Bionyra Pharma emerged from stealth earlier this year with $165m in series A financing and three in-licensed assets: a TL1A Mab, a TL1A*IL-23p19 bispecific, and an IL-25 Mab

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page